Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists

J Clin Invest. 2020 Jul 1;130(7):3345-3347. doi: 10.1172/JCI139642.

Maximilian F Konig^{1

2

3

4

5}, Mike Powell⁶, Verena Staedtke⁷, Ren-Yuan Bai⁸, David L Thomas⁹, Nicole Fischer⁵, Sakibul Huq⁸, Adham M Khalafallah⁸, Allison Koenecke¹⁰, Ruoxuan Xiong¹¹, Brett Mensh¹², Nickolas Papadopoulos^{1

2

3}, Kenneth W Kinzler^{1

2

3}, Bert Vogelstein^{1

2

3}, Joshua T Vogelstein⁶, Susan Athey¹³, Shibin Zhou^{1

2

3}, Chetan Bettegowda^{1

2

3

8}

¹ Ludwig Center.
² Lustgarten Laboratory, and.
³ Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA.
⁴ Division of Rheumatology.
⁵ Johns Hopkins University (JHU) School of Medicine, Baltimore, Maryland, USA.
⁶ Department of Biomedical Engineering, Institute of Computational Medicine, JHU, Baltimore, Maryland, USA.
⁷ Department of Neurology.
⁸ Department of Neurosurgery, and.
⁹ Division of Infectious Diseases, JHU School of Medicine, Baltimore, Maryland, USA.
¹⁰ Institute for Computational and Mathematical Engineering and.
¹¹ Management Science and Engineering, Stanford University, Stanford, California, USA.
¹² Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, Virginia, USA.
¹³ Stanford Graduate School of Business, Stanford University, Stanford, California, USA.

No abstract available

Keywords: COVID-19.

Publication types